An Introduction to Leukaemia
Treating leukaemia holds numerous challenges, including the need for less toxic and more cost-effective treatments. Important additions to the landscape include targeted treatments such as FLT3 inhibitors, BCL-2 inhibitors and immune therapies such as monoclonal antibodies, antibody-drug conjugates and chimeric antigen receptor (CAR) T-cell therapies have been important additions to improve patient outcomes.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Front-line consolidation therapy in B-ALL: current challenges and novel strategies
Watch adult and paediatric oncologists discuss unmet needs in front-line B-ALL consolidation and in-development novel strategies.
Robin Foà, EHA 2023: José Carreras Award presentation – research on Philadelphia-positive acute lymphoblastic leukaemia
Each year, the EHA Board presents the José Carreras Award to honour leaders in haematological research. touchONCOLOGY caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss his receipt of the José Carreras Award and the key take-home messages of his award presentation, which focused on Philadelphia-positive acute lymphoblastic leukaemia research. The presentation […]
Robin Foà, EHA 2023: New developments in the treatment of Philadelphia-positive acute lymphoblastic leukaemia
The management of patients with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) has evolved over the last few decades, with new and exciting treatments becoming increasingly available. We caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss the history of Ph+ ALL research and top trials in the treatment of Ph+ ALL. The […]
Arnon Kater, EHA 2023: MURANO substudy analysis: Venetoclax-rituximab in patients with chronic lymphocytic leukaemia
The phase III MURANO trial (NCT02005471) reported that venetoclax plus rituximab (venR) resulted in higher progression-free survival and overall survival than bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukaemia. The unmet needs in the treatment of chronic lymphocytic leukaemia, as well as the aims, main findings and clinical significance of the final MURANO […]
Elias Jabbour, ASCO 2023: PhALLCON: A phase 3 study comparing ponatinib vs imatinib patients with Ph+ALL
The randomized phase 3 PhALLCON trial was conducted in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. The practice-changing efficacy results and safety data demonstrate a potential for a new standard-of-care therapy for frontline use in this patient population and improvements in long-term survival outcomes. touchONCOLOGY spoke with editorial board member and principle investigator of the […]
Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
Experts answer questions with in-depth advice on the current clinical landscape and how new guidelines might impact regional clinical practice. Useful tips below will show how to navigate the activity.
- Describe the clinical presentation and the diagnostic process for MDS and AML
- Demonstrate how the pathophysiology of MDS and AML determines disease classification
- Outline the updated risk stratification guidelines for MDS and AML and the implications for patient management
Tackling unmet needs in chronic myeloid leukaemia: What’s next in the treatment algorithm?
Three experts consider unmet needs in chronic myeloid leukaemia and how new and emerging treatments may help address them.
- Summarize the rationale for new agents in CML in light of treatment safety considerations
- Discuss the unmet needs for patients with CML in later lines of therapy and how new agents may address these
- Explain how new and emerging agents may affect the treatment paradigm for patients with CML
Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]
Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]